Developer docs
API playgroundTry for free, no card

Search company profiles

Cytosurge

Full company profile

uuid000aedi

Namestring
Cytosurge
Legal namestring
Cytosurge AG
Websiteurl
cytosurge.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Cytosurge AG is a privately held Swiss biotechnology company founded in 2009 and headquartered in Zurich, that commercializes the patented FluidFM (Fluidic Force Microscopy) technology invented at ETH Zurich. FluidFM integrates atomic force microscopy with microfluidics through hollow, force-sensitive cantilever probes with apertures down to 300 nm, enabling sub-picoliter liquid handling, injection, extraction, and adhesion measurement at the single-cell level while preserving cell viability.

The company's commercial portfolio centers on two FluidFM system formats — the standalone semi-automated FluidFM OMNIUM platform and the FluidFM ADD-ON module that extends Bruker and Nanosurf AFM systems — together with a proprietary probe consumables line (Nanosyringe, Nanopipette, Micropipette) and ARYA operating software. On top of this hardware layer, Cytosurge operates the CellEDIT custom CRISPR cell line engineering service, which uses direct intra-nuclear CRISPR-Cas9 delivery via FluidFM to deliver monoclonal, vector-free edited mammalian cell lines in ten weeks, and the Live-seq temporal transcriptomics workflow, which pairs cytoplasmic biopsy extraction with Lexogen's RNA library prep to profile single-cell gene expression without killing the cell.

Cytosurge sells to academic research institutions and pharmaceutical/biotechnology companies through an enterprise field-sales motion supplemented by channel partners (Bruker, Nanosurf, Olympus) and regional distributors (Altium International for US & Canada, Cenibra GmbH for Europe), and lists its CellEDIT service on the scientist.com marketplace. Hardware, consumables, and professional services revenue streams are quote-based, with the probe consumables and service/recurring contracts forming a growing annuity-like layer on top of lumpy instrument placements across 140+ global installations.

Short descriptiontext

Cytosurge AG is a Zurich-based Swiss biotech that commercializes patented FluidFM (Fluidic Force Microscopy) technology and the CellEDIT CRISPR cell line engineering service, serving academic and pharmaceutical researchers performing single-cell injection, extraction, and editing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGlattbrugg, Switzerland
HQ citystring
Glattbrugg
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
atomic force microscopy, single-cell manipulation, CRISPR cell engineering, fluidic force microscopy, microfluidic probes
Industry2 codes
PRIMARYHLAGAIAD
Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations)
SECONDARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Services-Commercial Physical & Biological Research8731
Product category
Single-Cell Manipulation Instruments
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1FluidFM Systems (OMNIUM & ADD-ON)
TypeHardware Sales
Description

Sale of hardware instruments - the FluidFM OMNIUM standalone platform and FluidFM ADD-ON modules for third-party AFM systems. Includes associated software (ARYA software) for force control and workflow management.

cytosurge.com
2CellEDIT Service (CRISPR Cell Line Engineering)
TypeProfessional Services
Description

Custom CRISPR cell line engineering service delivered via direct intra-nuclear injection using FluidFM technology. Provides knockout, knock-in, and multiplex editing services with guaranteed deliverables in 10 weeks. Includes gRNA design, clone generation, and quality control reporting.

cytosurge.com
3FluidFM Probes & Consumables
TypeHardware Sales
Description

Sale of FluidFM probe consumables including Nanosyringes, Nanopipettes, Micropipettes, and biopsy kits. Probes come in various specifications and are tailored to specific AFM systems.

cytosurge.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1CellEDIT Custom CRISPR Cell Line Engineering - quote-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Custom project-based pricing determined after consultation. Includes: gRNA design, two edited clones, two wild type clones, full gRNA design report, final sequencing report, monoclonality proof, mycoplasma testing. Additional deliverables (extra clones, off-target analysis, extended QC) available on request at additional cost.

cytosurge.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1CellEDIT
Description

CRISPR Cell Line Engineering Service offering direct intra-nuclear delivery for precision gene editing

cytosurge.com
+4 more records
Core offering1 text field

Cytosurge develops and manufactures the patented FluidFM (Fluidic Force Microscopy) technology, which combines atomic force microscopy with microfluidics through hollow force-sensitive probes. The company sells the FluidFM OMNIUM standalone single-cell manipulation platform, the FluidFM ADD-ON module for third-party AFM systems, and a line of specialized FluidFM probes (Nanosyringe, Nanopipette, Micropipette). It also delivers the CellEDIT service for custom CRISPR cell line engineering via direct intra-nuclear delivery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Deliver edited monoclonal cell lines in 10 weeks
+4 more records
Product overview1 text field

Cytosurge offers a platform-based product portfolio centered on the FluidFM (Fluidic Force Microscopy) technology, which combines atomic force microscopy with microfluidics for single-cell manipulation. The core product is the FluidFM OMNIUM standalone platform, complemented by the FluidFM ADD-ON for integration with existing AFM systems. The product line includes specialized probes (Nanosyringe, Micropipette, Nanopipette) designed for different applications. Cytosurge provides the CellEDIT Service for custom CRISPR cell line engineering, and the FluidFM Biopsy Solution for temporal single-cell profiling using Live-seq technology. These products enable researchers to perform gentle single-cell injection, extraction, and manipulation while maintaining cell viability for applications in CRISPR gene editing, temporal transcriptomics, and mechanobiology.

Product and service3 records
1FluidFM OMNIUM Platform
CategoryInstrument / System
Description

Semi-automated standalone single-cell manipulation system combining atomic force microscopy with microfluidics for non-destructive injection, extraction, adhesion measurement, and pick-and-place of individual cells. Integrates Olympus IX83 microscope with environmental control (temperature/CO2) and up to 8 fluorescence filter sets.

2FluidFM ADD-ON
CategoryInstrument / Module
Description

Add-on module that extends existing Bruker and Nanosurf AFM systems with FluidFM microfluidic capabilities for single-cell force spectroscopy, nanoprinting, and bacterial adhesion measurement. Compatible with Bruker BioScope Resolve, JPK NanoWizard, CellHesion, ForceRobot, Nanosurf CoreAFM, FlexAFM, and DriveAFM platforms.

3FluidFM Nanosyringe
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-01-01
Description

Partnership for RNA analysis workflow integration with Live-seq technology. Lexogen provides the LUTHOR HD kit for high-definition single-cell 3' mRNA-seq library prep based on THOR technology for direct RNA amplification. Combined offering enables streamlined commercial workflow for Live-seq cytoplasmic biopsy collection and analysis.

Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

Regional distribution partnership started in 2024 covering US and Canada markets for FluidFM products and services.

Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-01-01
Description

European distribution partnership started in 2023 for FluidFM product distribution in covered territories.

4Harvard's Wyss Institute
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Collaboration to investigate CRISPR-based approaches for more effective introduction of multiple edits into single cells while minimizing CRISPR-related toxicity. Focus on multiplex gene editing research.

cytosurge.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Partnership to deliver complete single-cell and CRISPR genetic manipulation solutions. Olympus provides microscopy expertise complementing FluidFM technology for integrated single-cell solutions.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-01-01
Description

Premium partnership for distribution of FluidFM ADD-ON module compatible with Bruker BioScope Resolve, JPK NanoWizard, CellHesion, and ForceRobot AFM families. Bruker commercializes the FluidFM technology as an accessory for their bioAFM systems.

Strategic tierLegacyTypeChannel Partner/ Reseller/ DistributorAnnounced on2017-01-01
Description

Partnership (now part of Bruker) for FluidFM integration with JPK AFM systems including NanoWizard, CellHesion, and ForceRobot families.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2013-01-01
Description

Long-standing partnership for FluidFM ADD-ON distribution with Nanosurf CoreAFM, FlexAFM, and DriveAFM systems. Nanosurf provides FluidFM as an add-on capability for their AFM platforms.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Carl Zeiss Microscopy
TypeBroad incumbent
Description

Major microscopy and imaging incumbent serving life science research customers. The FluidFM OMNIUM platform is built on an Olympus IX83 microscope, indicating overlap in customer workflows requiring combined microscopy and manipulation.

TypeBroad incumbent
Description

Sequencing technology provider whose long-read platforms could be combined with FluidFM-derived samples. Both companies serve genomics and transcriptomics research customers at the intersection of novel sample prep and analysis.

TypeBroad incumbent
Description

Major AFM and life science tools incumbent that distributes Cytosurge's FluidFM ADD-ON module for its BioScope Resolve, JPK NanoWizard, CellHesion, and ForceRobot AFM systems. Bruker operates broadly across scientific instruments whereas Cytosurge specializes in single-cell manipulation.

TypeBroad incumbent
Description

Microscopy and imaging provider serving life science research. Overlaps with Cytosurge in integrated microscope-based single-cell workflows and competes for budget allocation within core imaging facilities.

TypeDirect peer
Description

Swiss-based AFM manufacturer and long-standing Cytosurge channel partner. Both companies serve the bio-AFM research market with complementary products; Nanosurf provides the AFM platforms while Cytosurge provides FluidFM add-on capabilities for single-cell applications.

TypeBroad incumbent
Description

Established single-cell biology tools provider with mass cytometry and microfluidic chip platforms. Targets similar academic and pharma customers for cell characterization and manipulation workflows.

TypeEmerging player
Description

Single-cell DNA and multi-omics analysis company serving pharma/biotech customers for cell line development and oncology applications. Overlaps with CellEDIT's pharma customer base in cell line characterization workflows.

TypeBroad incumbent
Description

Dominant single-cell genomics platform provider whose Chromium system competes conceptually with Cytosurge's Live-seq for transcriptomic profiling applications, though with fundamentally different technology.

TypeDirect peer
Description

Single-cell analysis and manipulation company offering picodroplet technology for cell isolation and analysis. Both companies address the single-cell biology research market with complementary platforms for manipulating and analyzing individual cells.

TypeEmerging player
Description

Single-cell sequencing company offering scalable single-cell RNA-seq without microfluidics. Competes with Live-seq for temporal transcriptomics customers but with a fundamentally different sample preparation approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cytosurge

Single-Cell Manipulation Instrumentscytosurge.com

Cytosurge AG is a Zurich-based Swiss biotech that commercializes patented FluidFM (Fluidic Force Microscopy) technology and the CellEDIT CRISPR cell line engineering service, serving academic and pharmaceutical researchers performing single-cell injection, extraction, and editing.

What Cytosurge does

Cytosurge AG is a privately held Swiss biotechnology company founded in 2009 and headquartered in Zurich, that commercializes the patented FluidFM (Fluidic Force Microscopy) technology invented at ETH Zurich. FluidFM integrates atomic force microscopy with microfluidics through hollow, force-sensitive cantilever probes with apertures down to 300 nm, enabling sub-picoliter liquid handling, injection, extraction, and adhesion measurement at the single-cell level while preserving cell viability.

The company's commercial portfolio centers on two FluidFM system formats — the standalone semi-automated FluidFM OMNIUM platform and the FluidFM ADD-ON module that extends Bruker and Nanosurf AFM systems — together with a proprietary probe consumables line (Nanosyringe, Nanopipette, Micropipette) and ARYA operating software. On top of this hardware layer, Cytosurge operates the CellEDIT custom CRISPR cell line engineering service, which uses direct intra-nuclear CRISPR-Cas9 delivery via FluidFM to deliver monoclonal, vector-free edited mammalian cell lines in ten weeks, and the Live-seq temporal transcriptomics workflow, which pairs cytoplasmic biopsy extraction with Lexogen's RNA library prep to profile single-cell gene expression without killing the cell.

Cytosurge sells to academic research institutions and pharmaceutical/biotechnology companies through an enterprise field-sales motion supplemented by channel partners (Bruker, Nanosurf, Olympus) and regional distributors (Altium International for US & Canada, Cenibra GmbH for Europe), and lists its CellEDIT service on the scientist.com marketplace. Hardware, consumables, and professional services revenue streams are quote-based, with the probe consumables and service/recurring contracts forming a growing annuity-like layer on top of lumpy instrument placements across 140+ global installations.

Cytosurge firmographics

Firmographics
Name
Cytosurge
Legal name
Cytosurge AG
Website
https://cytosurge.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Cytosurge AG is a Zurich-based Swiss biotech that commercializes patented FluidFM (Fluidic Force Microscopy) technology and the CellEDIT CRISPR cell line engineering service, serving academic and pharmaceutical researchers performing single-cell injection, extraction, and editing.
Ownership category
akta.pro rank

Cytosurge industry classification

Industry
Product category
Single-Cell Manipulation Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAIAD
Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations)
SECONDARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments

Keywords

  • Atomic force microscopy
  • Single-cell manipulation
  • CRISPR cell engineering
  • Fluidic force microscopy
  • Microfluidic probes

Where Cytosurge is headquartered

Location

Headquarters

HQ city
Glattbrugg
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Cytosurge business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. FluidFM Systems (OMNIUM & ADD-ON): Sale of hardware instruments - the FluidFM OMNIUM standalone platform and FluidFM ADD-ON modules for third-party AFM systems. Includes associated software (ARYA software) for force control and workflow management.
  2. CellEDIT Service (CRISPR Cell Line Engineering): Custom CRISPR cell line engineering service delivered via direct intra-nuclear injection using FluidFM technology. Provides knockout, knock-in, and multiplex editing services with guaranteed deliverables in 10 weeks. Includes gRNA design, clone generation, and quality control reporting.
  3. FluidFM Probes & Consumables: Sale of FluidFM probe consumables including Nanosyringes, Nanopipettes, Micropipettes, and biopsy kits. Probes come in various specifications and are tailored to specific AFM systems.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCellEDIT Custom CRISPR Cell Line Engineering - quote-based pricing

Go-to-market motion2 records

Distribution channels7 records

Marketing channels6 records

Cytosurge product offering

Product offering

Core offering

Cytosurge develops and manufactures the patented FluidFM (Fluidic Force Microscopy) technology, which combines atomic force microscopy with microfluidics through hollow force-sensitive probes. The company sells the FluidFM OMNIUM standalone single-cell manipulation platform, the FluidFM ADD-ON module for third-party AFM systems, and a line of specialized FluidFM probes (Nanosyringe, Nanopipette, Micropipette). It also delivers the CellEDIT service for custom CRISPR cell line engineering via direct intra-nuclear delivery.

Product overview

Cytosurge offers a platform-based product portfolio centered on the FluidFM (Fluidic Force Microscopy) technology, which combines atomic force microscopy with microfluidics for single-cell manipulation. The core product is the FluidFM OMNIUM standalone platform, complemented by the FluidFM ADD-ON for integration with existing AFM systems. The product line includes specialized probes (Nanosyringe, Micropipette, Nanopipette) designed for different applications. Cytosurge provides the CellEDIT Service for custom CRISPR cell line engineering, and the FluidFM Biopsy Solution for temporal single-cell profiling using Live-seq technology. These products enable researchers to perform gentle single-cell injection, extraction, and manipulation while maintaining cell viability for applications in CRISPR gene editing, temporal transcriptomics, and mechanobiology.

Differentiator

Problem solved

Functional benefit

Brands

  • CellEDIT: CRISPR Cell Line Engineering Service offering direct intra-nuclear delivery for precision gene editing
  • Live-seq
  • FluidFM
  • FluidFM OMNIUM
  • FluidFM ADD-ON

Products and services

  • FluidFM OMNIUM Platform Semi-automated standalone single-cell manipulation system combining atomic force microscopy with microfluidics for non-destructive injection, extraction, adhesion measurement, and pick-and-place of individual cells. Integrates Olympus IX83 microscope with environmental control (temperature/CO2) and up to 8 fluorescence filter sets.
  • FluidFM ADD-ON Add-on module that extends existing Bruker and Nanosurf AFM systems with FluidFM microfluidic capabilities for single-cell force spectroscopy, nanoprinting, and bacterial adhesion measurement. Compatible with Bruker BioScope Resolve, JPK NanoWizard, CellHesion, ForceRobot, Nanosurf CoreAFM, FlexAFM, and DriveAFM platforms.
  • FluidFM Nanosyringe

Quantifiable outcome

  • Deliver edited monoclonal cell lines in 10 weeks
  • +4 more outcomes

Companies that use Cytosurge

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Cytosurge technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature5 records

Cytosurge partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, regional, major and legacy.

  • LexogencoreTechnology or Integration · 1 January 2024Partnership for RNA analysis workflow integration with Live-seq technology. Lexogen provides the LUTHOR HD kit for high-definition single-cell 3' mRNA-seq library prep based on THOR technology for direct RNA amplification. Combined offering enables streamlined commercial workflow for Live-seq cytoplasmic biopsy collection and analysis.
  • Altium International Inc.regionalChannel Partner/ Reseller/ Distributor · 1 January 2024Regional distribution partnership started in 2024 covering US and Canada markets for FluidFM products and services.
  • Cenibra GmbHregionalChannel Partner/ Reseller/ Distributor · 1 January 2023European distribution partnership started in 2023 for FluidFM product distribution in covered territories.
  • Harvard's Wyss InstitutemajorStrategic or Co-development Partner · 1 January 2020Collaboration to investigate CRISPR-based approaches for more effective introduction of multiple edits into single cells while minimizing CRISPR-related toxicity. Focus on multiplex gene editing research.
  • Olympus Europe / Olympus AmericamajorStrategic or Co-development Partner · 1 January 2019Partnership to deliver complete single-cell and CRISPR genetic manipulation solutions. Olympus provides microscopy expertise complementing FluidFM technology for integrated single-cell solutions.
  • BrukercoreChannel Partner/ Reseller/ Distributor · 1 January 2018Premium partnership for distribution of FluidFM ADD-ON module compatible with Bruker BioScope Resolve, JPK NanoWizard, CellHesion, and ForceRobot AFM families. Bruker commercializes the FluidFM technology as an accessory for their bioAFM systems.
  • JPK InstrumentslegacyChannel Partner/ Reseller/ Distributor · 1 January 2017Partnership (now part of Bruker) for FluidFM integration with JPK AFM systems including NanoWizard, CellHesion, and ForceRobot families.
  • NanosurfcoreChannel Partner/ Reseller/ Distributor · 1 January 2013Long-standing partnership for FluidFM ADD-ON distribution with Nanosurf CoreAFM, FlexAFM, and DriveAFM systems. Nanosurf provides FluidFM as an add-on capability for their AFM platforms.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Cytosurge competitors and assessment

Company assessment

Broad incumbents

  • Carl Zeiss Microscopy: Major microscopy and imaging incumbent serving life science research customers. The FluidFM OMNIUM platform is built on an Olympus IX83 microscope, indicating overlap in customer workflows requiring combined microscopy and manipulation.
  • Oxford Nanopore Technologies: Sequencing technology provider whose long-read platforms could be combined with FluidFM-derived samples. Both companies serve genomics and transcriptomics research customers at the intersection of novel sample prep and analysis.
  • Bruker: Major AFM and life science tools incumbent that distributes Cytosurge's FluidFM ADD-ON module for its BioScope Resolve, JPK NanoWizard, CellHesion, and ForceRobot AFM systems. Bruker operates broadly across scientific instruments whereas Cytosurge specializes in single-cell manipulation.
  • Leica Microsystems (Danaher): Microscopy and imaging provider serving life science research. Overlaps with Cytosurge in integrated microscope-based single-cell workflows and competes for budget allocation within core imaging facilities.
  • Standard BioTools (formerly Fluidigm): Established single-cell biology tools provider with mass cytometry and microfluidic chip platforms. Targets similar academic and pharma customers for cell characterization and manipulation workflows.
  • 10x Genomics: Dominant single-cell genomics platform provider whose Chromium system competes conceptually with Cytosurge's Live-seq for transcriptomic profiling applications, though with fundamentally different technology.

Direct peers

  • Nanosurf: Swiss-based AFM manufacturer and long-standing Cytosurge channel partner. Both companies serve the bio-AFM research market with complementary products; Nanosurf provides the AFM platforms while Cytosurge provides FluidFM add-on capabilities for single-cell applications.
  • Sphere Fluidics: Single-cell analysis and manipulation company offering picodroplet technology for cell isolation and analysis. Both companies address the single-cell biology research market with complementary platforms for manipulating and analyzing individual cells.

Emerging players

  • Mission Bio: Single-cell DNA and multi-omics analysis company serving pharma/biotech customers for cell line development and oncology applications. Overlaps with CellEDIT's pharma customer base in cell line characterization workflows.
  • Parse Biosciences: Single-cell sequencing company offering scalable single-cell RNA-seq without microfluidics. Competes with Live-seq for temporal transcriptomics customers but with a fundamentally different sample preparation approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Cytosurge social profiles

Digital presence

Cytosurge financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cytosurge leadership team

Management profile

Number of profiles

Profiles16 records

Cytosurge subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Cytosurge funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cytosurge M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cytosurge

What does Cytosurge do?

Cytosurge develops and manufactures the patented FluidFM (Fluidic Force Microscopy) technology, which combines atomic force microscopy with microfluidics through hollow force-sensitive probes. The company sells the FluidFM OMNIUM standalone single-cell manipulation platform, the FluidFM ADD-ON module for third-party AFM systems, and a line of specialized FluidFM probes (Nanosyringe, Nanopipette, Micropipette). It also delivers the CellEDIT service for custom CRISPR cell line engineering via direct intra-nuclear delivery.

Is Cytosurge a public or private company?

Cytosurge is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Cytosurge founded?

Cytosurge was founded in 2009. It employs 11 to 50 people.

Where is Cytosurge based?

Cytosurge is headquartered in Glattbrugg, Switzerland, in the Europe region.

How does Cytosurge make money?

Three revenue lines are on record. FluidFM Systems (OMNIUM & ADD-ON) is the primary driver. The others are cellEDIT Service (CRISPR Cell Line Engineering) and fluidFM Probes & Consumables.

Who are Cytosurge's main competitors?

Broad incumbents on record are Carl Zeiss Microscopy, Oxford Nanopore Technologies, Bruker, Leica Microsystems (Danaher), Standard BioTools (formerly Fluidigm) and 10x Genomics. Direct peers are Nanosurf and Sphere Fluidics. Emerging players are Mission Bio and Parse Biosciences.

Does Cytosurge have an API?

No public API is recorded for Cytosurge.

What industry is Cytosurge in?

Cytosurge's product category is Single-Cell Manipulation Instruments. Its primary akta.pro industry code is HLAGAIAD, Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations), with a secondary code of HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments. Its NAICS code is 334516 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageCytosurge elects veteran biotech executive, investor, and company builder Luba Greenwood, J.D., to its Board of DirectorsCytosurge, a Swiss biotech company pioneering Same-Cell Biology, announced the election of Luba Greenwood to its Board of Directors, effective July 9, 2026. Greenwood is a veteran biotech executive, investor, and company builder who currently serves as CEO of Mwyngil Therapeutics and brings extensive experience in venture capital, including founding Dana-Farber's venture fund, as well as leadership roles at Google Life Sciences (Verily), Roche, and Harvard Business School. The appointment is intended to support Cytosurge's expansion into the US market and its growth strategy as it scales its proprietary FluidFM technology platform and causal biological data offerings for AI-driven drug discovery.GlobeNewswireCytosurge elects veteran biotech executive, investor, and company builder Luba Greenwood, J.D., to its Board of DirectorsCytosurge, a Swiss biotech company pioneering Same-Cell Biology, announced the election of Luba Greenwood to its Board of Directors, effective July 9, 2026. Greenwood is a veteran biotech executive and investor who currently serves as CEO of Mwyngil Therapeutics and holds board positions including MassBio, bringing venture capital experience from founding Dana-Farber's venture fund. The appointment is intended to support Cytosurge's expansion into the US market and its strategy to generate causal biological data for AI-driven drug discovery through its proprietary FluidFM technology platform.FinancialContent Business PageCytosurge’s CellEDIT Conquers "Impossible" Genome Engineering ChallengesCytosurge AG and the Technical University of Denmark published a peer-reviewed study in JCI Insight validating CellEDIT's ability to overcome barriers in editing fragile human keratinocytes, enabling previously inaccessible cellular processes. The research uncovered dermokine's role in skin cell adhesion and wound healing, with direct implications for chronic ulcer treatment and epithelial skin cancer. This validation positions CellEDIT as a tool for tackling supposedly "impossible" CRISPR edits in difficult-to-engineer cell models while preserving true biological phenotypes.GlobeNewswireCytosurge’s CellEDIT Conquers "Impossible" Genome Engineering ChallengesCytosurge AG and the Technical University of Denmark co-published a peer-reviewed study in JCI Insight validating CellEDIT's ability to edit difficult-to-engineer human keratinocytes, uncovering dermokine's role in skin cell adhesion with implications for chronic wound healing and epithelial skin cancers. The technology enabled multi-guide CRISPR editing with controlled dosing and minimal cellular stress, producing reliable biological replicates that traditional bulk delivery methods cannot achieve. Researchers validated findings in patient tissue with chronic non-healing wounds, demonstrating direct translation from lab discoveries to real-world tissue repair challenges.BioSpaceCytosurge’s CellEDIT Conquers “Impossible” Genome Engineering ChallengesCytosurge and DTU published a study in JCI Insight validating CellEDIT's ability to edit human keratinocytes, uncovering dermokine's role in skin cell adhesion. The research identifies dermokine as a regulator of keratinocyte differentiation and adhesion, with implications for chronic ulcers and skin cancer. The findings were validated in patient tissue from chronic wounds.GenomeWebCytosurge Eyes Slice of Single-Cell Market With Live-seq TechnologySwiss biotech company Cytosurge has launched Live-seq, a commercial single-cell RNA sequencing workflow for live cells, using its FluidFM Omnium platform in partnership with Austrian RNA technology firm Lexogen. The method enables temporal single-cell profiling while preserving cell viability through minimally invasive cytoplasmic sampling, with extraction times of six to 10 minutes per cell. The company plans to boost throughput of the workflow and launch a next-generation FluidFM Omnium system with drastically increased capacity within five years.GlobeNewswireCytosurge Appoints Magid Haddouchi as Chief Commercial OfficerCytosurge AG appointed Magid Haddouchi as Chief Commercial Officer, effective April 1, 2025. He brings over 15 years of experience and will lead commercial growth and partnerships. The company will attend the AACR Annual Meeting and other events in 2025.GlobeNewswireCytosurge Announces Strategic Leadership TransitionCytosurge AG announced a leadership transition effective January 1, 2025, appointing Simon Egli as CEO, with Pascal Behr remaining on the Board as Delegate. The move follows over 140 FluidFM systems installed globally and 150+ publications. Egli brings over a decade of life sciences leadership experience.GlobeNewswireCytosurge and Lexogen Partner to Advance Live-Cell SequencingCytosurge and Lexogen announced a partnership to advance live-cell sequencing, integrating Cytosurge's FluidFM OMNIUM platform with Lexogen's LUTHOR HD kit. The collaboration aims to provide a scalable workflow for analyzing transcriptomes of living cells over time, with LUTHOR detecting thousands of genes from RNA as low as 0.15 pg.